How nasal and gut bacteria shape allergic rhinitis in kids
Official title: Integrated role of nasal airway & gut microbiome dynamics in allergic rhinitis
Funded at Massachusetts General Hospital · NIH-11269734 · Data updated 2026-11-12
A pediatric-focused project will follow healthy infants over time to see how the nose and gut bacteria relate to developing allergic rhinitis by age 7.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $828,519 |
| NIH project number | 1R01AI195887-01 |
| Project ID | NIH-11269734 on NIH RePORTER |
Who could benefit from this research
✓Could help
Infants enrolled in or similar to the MARC-43 multicenter cohort, followed through age 2 with long-term follow-up for AR development.
✕Less likely to help
Children outside the cohort or without longitudinal sample collection may not benefit from these findings.
What this research studies
This study will build on a large, ongoing infant cohort to track changes in nasal airway and gut bacteria from ages 0 to 2 and relate them to later allergic rhinitis. Researchers will use 16S sequencing to profile microbiomes and integrate this with genetic and clinical data to identify patterns linked to AR. The goal is to understand how microbiome dynamics may contribute to AR risk and its subtypes, with the aim of informing prevention or early intervention strategies. Results could help families understand risk factors and pave the way for microbiome-based approaches in pediatric care.
Why it matters
Potential benefit: If successful, the findings could guide early prevention strategies and personalized care for children at risk of allergic rhinitis.
How similar studies have gone: Prior studies linking microbiome profiles to AR risk exist, but this project advances by tracking dual nasal and gut microbiomes over time.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Camargo, Carlos Arturo — Massachusetts General Hospital
- Study coordinator: Camargo, Carlos Arturo
Related research
Other NIH-funded projects on the same topics.
-
Multi-agent AI to annotate enzymes in the human gut microbiome
A team at a major university will build an AI system that automatically curates and labels the functions of enzymes in the human gut microbiome to speed up understanding their health effects.
-
Mapping how gut bacteria transform drugs
Scientists will study how the gut microbiome changes thousands of drugs into new forms, which could affect how well a medicine works or whether it causes side effects.
-
Aflatoxin exposure and child growth in Guatemala
A study in rural Guatemala will track how exposure to aflatoxin relates to growth and gut health in young children.
-
Gut bacteria that can make cancer immunotherapy less effective
This project will see if reducing chronic inflammation driven by certain gut bacteria can help immunotherapy work better for people whose cancers have stopped responding.
-
How gut bacteria affect how cancer drugs work
This project looks at how the bacteria in your gut might change how well and with what side effects fluoropyrimidine cancer drugs like 5-FU work in people.
-
Gut bacteria and cancer drugs: how your gut may change chemotherapy effectiveness
This project studies how the gut microbiome might affect how well certain chemotherapy drugs work and their side effects in people with cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.